TheraTomebio - previously dba NeuroFx - is developing an innovative, cell-free therapeutic factor concentrate derived from adult adipose (fat) stem cells (NFx101). Thera-101 (previously NFx101) - an injectable biologic drug designed to be first-line therapy for ischemic brain injury, including stroke - has demonstrated great potential to halt brain injury caused by stroke, promote regeneration and repair of brain tissues, and, most impressively, re-establish normal function in animals. NFx-101 is a platform technology that has potential to be successfully used in non-neurological conditions (e.g., musculoskeletal, dermatologic, cardiovascular) as well. The plan is that NeuroFx will create value in these non-core indications by partnering with biopharmaceutical, regenerative medicine or cosmetic companies.
